Merck to Aquire Terns Pharmaceuticals Expanding Its Hematology Pipeline with Tern-701, A Novel Candidate for Chronic Myeloid Leukemia

Merck & Terns Pharmaceuticals in the NEWS

 March 25, 2026 (GLOBE NEWSWIRE) -- Merck (MRK) - known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (This content is for paid subscribers.

Please click here to subscribe or here to log in.